BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 21236521)

  • 1. Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment.
    Musilek K; Komloova M; Holas O; Hrabinova M; Pohanka M; Dohnal V; Nachon F; Dolezal M; Kuca K
    Eur J Med Chem; 2011 Feb; 46(2):811-8. PubMed ID: 21236521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment.
    Komloova M; Musilek K; Horova A; Holas O; Dohnal V; Gunn-Moore F; Kuca K
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2505-9. PubMed ID: 21397501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications.
    Musilek K; Komloova M; Zavadova V; Holas O; Hrabinova M; Pohanka M; Dohnal V; Nachon F; Dolezal M; Kuca K; Jung YS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1763-6. PubMed ID: 20138518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The preparation, in vitro screening and molecular docking of symmetrical bisquaternary cholinesterase inhibitors containing a but-(2E)-en-1,4-diyl connecting linkage.
    Musilek K; Pavlikova R; Marek J; Komloova M; Holas O; Hrabinova M; Pohanka M; Dohnal V; Dolezal M; Gunn-Moore F; Kuca K
    J Enzyme Inhib Med Chem; 2011 Apr; 26(2):245-53. PubMed ID: 21406034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation, in vitro evaluation and molecular modelling of pyridinium-quinolinium/isoquinolinium non-symmetrical bisquaternary cholinesterase inhibitors.
    Komloova M; Horova A; Hrabinova M; Jun D; Dolezal M; Vinsova J; Kuca K; Musilek K
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6663-6. PubMed ID: 24220173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation, in vitro screening and molecular modelling of symmetrical 4-tert-butylpyridinium cholinesterase inhibitors--analogues of SAD-128.
    Musilek K; Roder J; Komloova M; Holas O; Hrabinova M; Pohanka M; Dohnal V; Opletalova V; Kuca K; Jung YS
    Bioorg Med Chem Lett; 2011 Jan; 21(1):150-4. PubMed ID: 21144749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease.
    Korabecny J; Musilek K; Holas O; Binder J; Zemek F; Marek J; Pohanka M; Opletalova V; Dohnal V; Kuca K
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6093-5. PubMed ID: 20817518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
    Tasso B; Catto M; Nicolotti O; Novelli F; Tonelli M; Giangreco I; Pisani L; Sparatore A; Boido V; Carotti A; Sparatore F
    Eur J Med Chem; 2011 Jun; 46(6):2170-84. PubMed ID: 21459491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New potent human acetylcholinesterase inhibitors in the tetracyclic triterpene series with inhibitory potency on amyloid β aggregation.
    Rouleau J; Iorga BI; Guillou C
    Eur J Med Chem; 2011 Jun; 46(6):2193-205. PubMed ID: 21435752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
    Yu Q; Holloway HW; Utsuki T; Brossi A; Greig NH
    J Med Chem; 1999 May; 42(10):1855-61. PubMed ID: 10346939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 1,3,4-thiadiazole analogues as novel AChE and BuChE inhibitors.
    Skrzypek A; Matysiak J; Niewiadomy A; Bajda M; Szymański P
    Eur J Med Chem; 2013 Apr; 62():311-9. PubMed ID: 23376249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
    Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
    Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7-MEOTA-donepezil like compounds as cholinesterase inhibitors: Synthesis, pharmacological evaluation, molecular modeling and QSAR studies.
    Korabecny J; Dolezal R; Cabelova P; Horova A; Hruba E; Ricny J; Sedlacek L; Nepovimova E; Spilovska K; Andrs M; Musilek K; Opletalova V; Sepsova V; Ripova D; Kuca K
    Eur J Med Chem; 2014 Jul; 82():426-38. PubMed ID: 24929293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation.
    Belluti F; Rampa A; Piazzi L; Bisi A; Gobbi S; Bartolini M; Andrisano V; Cavalli A; Recanatini M; Valenti P
    J Med Chem; 2005 Jun; 48(13):4444-56. PubMed ID: 15974596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic acyl guanidines bearing carbamate moieties allow potent and dirigible cholinesterase inhibition of either acetyl- or butyrylcholinesterase.
    Darras FH; Kling B; Sawatzky E; Heilmann J; Decker M
    Bioorg Med Chem; 2014 Sep; 22(17):5020-34. PubMed ID: 25059502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors.
    Razavi SF; Khoobi M; Nadri H; Sakhteman A; Moradi A; Emami S; Foroumadi A; Shafiee A
    Eur J Med Chem; 2013 Jun; 64():252-9. PubMed ID: 23644208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homodimeric bis-quaternary heterocyclic ammonium salts as potent acetyl- and butyrylcholinesterase inhibitors: a systematic investigation of the influence of linker and cationic heads over affinity and selectivity.
    Conejo-García A; Pisani L; Núñez Mdel C; Catto M; Nicolotti O; Leonetti F; Campos JM; Gallo MA; Espinosa A; Carotti A
    J Med Chem; 2011 Apr; 54(8):2627-45. PubMed ID: 21417225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bivalent 5,8,9,13b-tetrahydro-6H-isoquino[1,2-a]isoquinolines and -isoquinolinium salts: novel heterocyclic templates for butyrylcholinesterase inhibitors.
    Schulze M; Siol O; Decker M; Lehmann J
    Bioorg Med Chem Lett; 2010 May; 20(9):2946-9. PubMed ID: 20350808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
    Brunhofer G; Fallarero A; Karlsson D; Batista-Gonzalez A; Shinde P; Gopi Mohan C; Vuorela P
    Bioorg Med Chem; 2012 Nov; 20(22):6669-79. PubMed ID: 23062825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel alkyl- and arylcarbamate derivatives with N-benzylpiperidine and N-benzylpiperazine moieties as cholinesterases inhibitors.
    Więckowska A; Bajda M; Guzior N; Malawska B
    Eur J Med Chem; 2010 Dec; 45(12):5602-11. PubMed ID: 20926161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.